Telangana: Aurobindo Pharma has announced that Apitoria Pharma Private Limited, a wholly-owned subsidiary of the Company has appointed Dr. Sanjay Chaturvedi as CEO and Ch. Venkat Nageswar as Independent Director with effect from April 4, 2023.
Prior to this role, Dr.Sanjay was associated with IOL Chemicals and Pharma as Executive Director & CEO. Dr Sanjay is a Ph D in Physical Chemistry from State University of New York and Management Degree from Wharton Business School.
April 30, 2021. With over 37 years of experience spanning across various distinguished positions in the Bank pan
India and abroad, he worked in all the areas of Banking – Credit, Treasury, Retail, International Banking, Finance,
Risk Management etc. He has also held CFO position of the Bank for a brief period.
Mr. Venkat, post superannuation, has been nominated as non-official member for Board for Trade by GOI,
Member – Advisory committee of SREI Group of companies by RBI, Member – Empowered Committee to approve
ECBs and ODIs by RBI. Apart from this, he is financial advisor to Indian Railway Finance Corporation and on the
Boards of NCDEX, Axis MF Trustee, IDBI Capital Markets & Securities Ltd, Financial Benchmarks India Pvt. Ltd.
and Svamaan Financial Services Pvt. Ltd.
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 24 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, AntiRetroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic.